BAY 1093884

Drug Profile

BAY 1093884

Alternative Names: Anti-TFPI antibody; BAY-109; BAY1093884

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haemophilia

Most Recent Events

  • 29 Mar 2018 Bayer plans a phase I trial in Haemophilia (Treatment-experienced) in Israel (NCT03481946)
  • 15 Jun 2015 Pharmacodynamics data from a preclinical trial in haemophilia released by Bayer
  • 01 Mar 2015 Phase-I clinical trials in Haemophilia in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top